Researchers are excitedly focused on retatrutide, a promising drug from Eli Lilly, as a possible breakthrough in body reduction . Different than many previous approaches, retatrutide is a twin-action compound targeting both GLP-1 and GIP, substances that affect hunger and blood sugar regulation . In